Searched for
GSK SANOFI
Drugmaker GSK settles another California lawsuit on heartburn drug ZantacGlaxoSmithKline (GSK) has announced that it will confidentially settle another lawsuit in California regarding its discontinued heartburn d...- No plans to reintroduce Zinetac in India: GSKBritish drugmaker GSK said it has no plans to reintroduce its once top-selling heartburn medication Zinetac (ranitidine) brand in India, de...
- Will PLI help Indian pharma gain market share at cost of MNCs?Indian pharmaceutical companies are becoming more aggressive and increasing their market share and capex. Companies such as Divis, Dr Reddy...
- European shares eke out gains at open as healthcare stocks reboundSanofi rose 1.6% and GSK added 3.0% after a heavy selloff in the previous session on growing worries about U.S. litigation focused on a hea...
- Sanofi, GSK variant-specific Covid-19 shot found effective against Omicron"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron varian...
- Sanofi, GSK receive nod for Phase 3 trial of COVID-19 vaccine candidate in IndiaThe design of the Phase 3 study, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate...
- Sanofi-GSK reports success in Covid-19 vaccine, after setbackThe drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vac...
- GSK, Sanofi say COVID-19 shot won't be ready until late 2021The companies said early trials showed the vaccine produced an "insufficient" immune response in older adults, demonstrating the need to re...
- GSK, Sanofi to make 200 mn doses available for COVID-19 vaccine allianceCOVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan. The Unit...
- Sanofi and GSK launch trial for COVID-19 protein-based vaccineSanofi and GSK said in a joint statement on Thursday they had started the "Phase 1/2" trial for their adjuvanted COVID-19 vaccine, which th...
- Sanofi to enroll thousands for its coronavirus vaccine trialsSanofi is working on two vaccine projects to prevent COVID-19 - the illness caused by the new coronavirus - and said it is exploring severa...
- GSK, Sanofi team up to bring out Covid-19 vaccineTwo of the world's largest vaccine manufacturers, Sanofi and GlaxoSmithKline, are coming together to work on a Covid-19 vaccine, which if i...
- Sanofi, Boehringer Ingelheim seek CCI nod for $25-billion global asset swap dealThe commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition.
- Glaxo considering all options against CCI orderSlapped with a penalty of nearly Rs 61 crore by competition watchdog CCI, GlaxoSmithKline Pharmaceuticals today said it would review the or...
- Competition Commission of India to investigate government tender to GSK, SanofiCCI has initiated an investigation into the tendering process to procure Meningitis for the Haj pilgrims, after a complaint filed by Bio-Me...
- Govt's meningitis vaccine tendering process under CCI scanner for 'favouring GSK, Sanofi'Bio-Med says govt tweaked tender rules to favour GSK, Sanofi, particularly the condition that firms must have Rs 50 cr turnover for last 3 ...
- Sanofi, Novartis and GSK in race to buy Elder Pharma's domestic formulations businessSanofi, Novartis and GSK are in the race to buy out the domestic formulations business of debt-ridden Elder Pharmaceuticals.
- More drug MNCs join the stake-hike bandwagonAfter the two leading pharma multinationals recently increased their stakes in their Indian units, people connected with the industry say t...
- Sanofi Aventis's Piramal plans fall throughFrench pharma major Sanofi Aventis's plans to acquire a majority stake in Mumbai-based Piramal Healthcare has fallen through due to differe...
- Piramal Health may rope in Credit Suisse for dealThe healthcare major has roped in investment bank Credit Suisse as an advisor for a likely deal, according to sources close to the developm...
Load More
